for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY

Latest Trade

62.09USD

Change

0.81(+1.32%)

Volume

19,225,166

Today's Range

60.93

 - 

62.37

52 Week Range

42.48

 - 

62.37

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
61.28
Open
61.03
Volume
19,225,166
3M AVG Volume
351.79
Today's High
62.37
Today's Low
60.93
52 Week High
62.37
52 Week Low
42.48
Shares Out (MIL)
2,344.19
Market Cap (MIL)
143,652.20
Forward P/E
14.12
Dividend (Yield %)
2.94

Next Event

Dividend For BMY.N - 0.4500 USD

Latest Developments

More

Bristol-Myers Squibb Presents Overall Survival And Safety Data From Pivotal CC-486 Study QUAZAR AML-001

Bristol-Myers Trial To Treat Anemia In Rare Blood Diseases Showed Sustained Clinical Benefit In Late-Stage Trial

Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

Charles A. Bancroft

Chief Financial Officer, Executive Vice President - Global Business Operations

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President

Sandra Leung

Executive Vice President, General Counsel

Christopher S. Boerner

Executive Vice President and Chief Commercial Officer

Key Stats

2.07 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

19.4K

2017

20.8K

2018

22.6K

2019(E)

24.3K
EPS (USD)

2016

2.830

2017

3.010

2018

3.980

2019(E)

4.339
Price To Earnings (TTM)
17.71
Price To Sales (TTM)
5.94
Price To Book (MRQ)
5.66
Price To Cash Flow (TTM)
22.33
Total Debt To Equity (MRQ)
141.43
LT Debt To Equity (MRQ)
138.20
Return on Investment (TTM)
16.07
Return on Equity (TTM)
12.47

Latest News

Latest News

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial.

UPDATE 1-Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.

UPDATE 1-Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.

Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. (Reporting by Diane Bartz; Editing by Sandra Maler)

Bristol-Myers posts better-than-expected results, Opdivo growth slows

U.S. drugmaker Bristol-Myers Squibb Co <BMY.N> reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.

Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise

Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients.

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday...

UPDATE 1-Bristol-Myers' Opdivo fails to meet goal of brain tumor study

Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that affects the brain and spine.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co <BMY.N>, which is set to buy biotechnology company Celgene Corp <CELG.O> for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers releases mixed Opdivo lung cancer results

Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol-Myers' Opdivo fails late-stage brain cancer trial

Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up